TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

J&J wins U.S. approval for TB tablet

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

JNJ $70.10 +$0.62

at close on MONDAY

By Anna Edney C.2012 Bloomberg News
Monday, Dec. 31, 2012, 10:30 p.m.
 

Johnson & Johnson won regulatory approval for its tuberculosis tablet Sirturo, the first drug in 40 years that provides a new way to treat the contagious lung infection.

The Food and Drug Administration cleared Sirturo to be added to therapies for use by adults whose illness is resistant to multiple medicines, the New Brunswick, N.J.- based company said Monday.

While tuberculosis was once the leading cause of death in the nation, the drug-resistant version of the illness affected about 98 people last year, according to the Centers for Disease Control and Prevention.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Faulty air bags in 30M vehicles
  2. Amazon investors’ patience wears thin
  3. Toyota Yaris adds French flair for ’15
  4. First Niagara sets aside $45 million
  5. Mini goes mainstream
  6. Stocks rise broadly on earnings; Amazon sinks
  7. Bond mutual funds continue to carry their weight
  8. Motoring Q&A: ‘Check engine’ light doesn’t reset itself
  9. Sell-off reins in complacency
  10. Natrona Bottling Co. keeps soda pop operation focused on craft, taste
  11. Rule to close coal royalty loophole
Subscribe today! Click here for our subscription offers.